FORM 4

Check this box if no longer subject to

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours nor response.	0.5								

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Chodakewitz Jeffrey</u>					V	2. Issuer Name and Ticker or Trading Symbol  VERTEX PHARMACEUTICALS INC /  MA [ VRTX ]								(Che	ck all applic	able)	10% Own		ner
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 02/03/2017									below)	EVP GM	DA, (	below)	респу	
(Street) BOSTON MA 02210  (City) (State) (Zip)				- 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable lee)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Noi	n-Deri	vativ	e Se	curities	Acc	quired,	Dis	posed o	f, or B	enef	icially	Owned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.					4 and Securitie Benefici		s ally following	Form	: Direct   C Indirect   E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or F	Price	Transact (Instr. 3 a	tion(s)			(111341. 4)
Common Stock 02/03/3					3/201	/2017			A		4,794	(1)	1	\$0.01	115,497			D	
Common Stock 02/03/				3/201	/2017			A		12,136	(2)	1	\$0.00	127	,633		D		
		-	Гable II -								osed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Trans Code			of		6. Date Exercisa Expiration Date (Month/Day/Yea		of Secu Underly Derivati		tle and Amount ecurities erlying vative Security tr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisabl		Expiration Date	Title	or Nu of	ount mber ares					
Stock Option (Right to	\$86.52	02/03/2017			A		24,852		(3)	C	2/02/2027	Commo Stock	<sup>1</sup> 24	,852	\$0.00	24,852	2	D	

## **Explanation of Responses:**

- 1. Represents earned performance shares with respect to a performance stock unit award granted on 2/02/2016 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2017. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.
- 2. Restricted stock unit award that vests in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020.
- 3. The option vests in 16 quarterly installments from 02/03/2017.

## Remarks:

02/07/2017 Omar White, Attorney-In-Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.